Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue

There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD. Below are the details in descending order of performance.

  1. Seelos (SEEL): UP 7.6% this week; UP 6.5% MTD
  2. Compass Pathways (CMPS): UP 2.7% this week; UP 9.7% MTD
    • is primarily focused on the use of psilocybin* (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
  3. Atai (ATAI); UP 2.3% this week; No Change MTD
  4. Mind Medicine (MNMD): UP 1.4% this week; UP 4.8% MTD
  5. Incannex Healthcare (IXHL): No Change this week; UP 2.1% MTD
  6. GH Research (GHRS): DOWN 1.6% this week; UP 8.6% MTD

*Read 10 Psychedelic Substances And The 36 Companies Researching Them for a description of each of the psychedelic-based compounds mentioned in this article.


The munKNEE Psychedelic Drug Stocks Index is up 0.6% this week and is now up 7.3% MTD.

If you are interested in this category of clinical-stage psychedelic compound-based stocks consider the  AdvisorShares Psychedelic ETF (PSIL) which consists of 23 such stocks - but keep in mind that the vast majority have market capitalizations of $50M or less (i.e. are nano-caps). It is up 2.2% MTD and is now up 8.2% MTD.

More By This Author:

Increase In Beyond Meat's Short Interest Percentage Propels Plant-Based Food Stocks Index
Majority of American MSOs Down MTD, Again, Led By Trulieve
Artificial Intelligence (AI) Stocks: In A Bubble Or Not?

Disclosure: None

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.